These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 21699091

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Organic solvents in the pharmaceutical industry.
    Grodowska K, Parczewski A.
    Acta Pol Pharm; 2010; 67(1):3-12. PubMed ID: 20210074
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Substandard medicines in resource-poor settings: a problem that can no longer be ignored.
    Caudron JM, Ford N, Henkens M, Macé C, Kiddle-Monroe R, Pinel J.
    Trop Med Int Health; 2008 Aug; 13(8):1062-72. PubMed ID: 18631318
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organ Tech Rep Ser; 1999 Aug; 885():i-vi, 1-156. PubMed ID: 10352573
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. China's perspective on similar biotherapeutic products.
    Liang C, Wang J.
    Biologicals; 2011 Sep; 39(5):312-6. PubMed ID: 21924622
    [Abstract] [Full Text] [Related]

  • 11. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organization.
    World Health Organ Tech Rep Ser; 2005 Sep; 929():1-142, backcover. PubMed ID: 16353684
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characterization and establishment of specifications for biopharmaceuticals.
    Davis GC, Riggin RM.
    Dev Biol Stand; 1997 Sep; 91():49-54. PubMed ID: 9413683
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Quality, safety and efficacy of follow-on biologics in Japan.
    Yamaguchi T, Arato T.
    Biologicals; 2011 Sep; 39(5):328-32. PubMed ID: 21890377
    [Abstract] [Full Text] [Related]

  • 16. The regulatory framework for similar biotherapeutic products in Cuba.
    Hechavarría Núñez Y, Pérez Massipe RO, Orta Hernández SD, Muñoz LM, Jacobo Casanueva OL, Pérez Rodríguez V, Domínguez Morales RB, Pérez Cristiá RB.
    Biologicals; 2011 Sep; 39(5):317-20. PubMed ID: 21930393
    [Abstract] [Full Text] [Related]

  • 17. Concept of biosimilar products in Jordan.
    Haddadin RD.
    Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Guidelines for introducing new drugs for medical use in Poland and control of their quality].
    Danysz A.
    Pol Tyg Lek; 2011 Sep; 39(51-52):1673-4. PubMed ID: 6522321
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.